Savara (SVRA) Shares Outstanding (2010 - 2026)
Savara (SVRA) posted quarterly Shares Outstanding (Entity) of $204.9 million for Q1 2026, down 5.19% year-over-year from $216.1 million in Q1 2025, and little changed quarter-over-quarter from $204.6 million in Q4 2025.
Savara (SVRA) Shares Outstanding (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Shares Outstanding (Entity) for 17 consecutive years, with $204.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) fell 5.19% year-over-year to $204.9 million; the TTM figure through Mar 2026 stood at $204.9 million (down 5.19% YoY), while the FY2025 annual figure was $204.6 million, up 18.64% from the prior year.
- Shares Outstanding (Entity) steadied at $204.9 million in Q1 2026 per SVRA's latest filing, from $204.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $216.5 million in Q3 2025 and bottomed at $135.3 million in Q3 2023.
- Historically, Shares Outstanding (Entity) has averaged $173.9 million across 5 years, with a median of $170.8 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 98.42% — and 2023, when it fell 11.41%.
- Savara's Shares Outstanding (Entity) stood at $152.8 million in 2022, then fell by 9.58% to $138.1 million in 2023, then grew by 24.81% to $172.4 million in 2024, then advanced by 18.64% to $204.6 million in 2025, then gained by 0.17% to $204.9 million in 2026.
- Business Quant data shows SVRA's Shares Outstanding (Entity) at $204.9 million in Q1 2026, $204.6 million in Q4 2025, and $216.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 253.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.57 Mn |
| Mar 31, 2026 | 253.28 Mn |
| Dec 31, 2025 | 222.39 Mn |
| Sep 30, 2025 | 216.46 Mn |
| Jun 30, 2025 | 216.43 Mn |
| Mar 31, 2025 | 216.15 Mn |
| Dec 31, 2024 | 198.19 Mn |
| Sep 30, 2024 | 211.85 Mn |
| Jun 30, 2024 | 182.58 Mn |
| Mar 31, 2024 | 182.55 Mn |
| Dec 31, 2023 | 165.20 Mn |
| Sep 30, 2023 | 164.34 Mn |
| Jun 30, 2023 | 152.80 Mn |
| Mar 31, 2023 | 152.78 Mn |
| Dec 31, 2022 | 152.77 Mn |
| Sep 30, 2022 | 152.77 Mn |
| Jun 30, 2022 | 152.77 Mn |
| Mar 31, 2022 | 152.77 Mn |
| Dec 31, 2021 | 133.92 Mn |
| Sep 30, 2021 | 152.59 Mn |